

Medicare D Cap Means Some Patients Stop Drugs

BY TIMOTHY F. KIRN
Sacramento Bureau

SEATTLE — Patients taking antidepressants and cholesterol-lowering drugs who are in pharmacy-capped plans, like the new Medicare Part D drug benefit, often stop taking their drugs when they reach the cap, Geoffrey Joyce, Ph.D., said at the annual research meeting of Academy Health.

According to his research, anywhere from 6% to 11% of patients in the

Medicare Part D program are likely to hit what is known as the “doughnut hole” of coverage in any given year, said Dr. Joyce, a senior economist with the RAND Corp., Santa Monica, Calif.

The so-called doughnut hole is the gap in coverage that goes into effect during a coverage year when a patient’s drug expenditures reach \$2,250, and continues until the expenditures reach \$5,100. Prior to reaching the doughnut-hole gap, beneficiaries have a \$250 annual deductible and

pay 25% of their drug costs. After expenditures have reached \$5,100, catastrophic coverage kicks in and patients pay only 5% of costs. Within the doughnut hole, patients pay 100% of their drug costs.

Many health economists and others have worried that the Medicare Part D patients most likely to spend their way into the doughnut hole are the sickest patients, and that those patients might become non-compliant with their medication regimens when they surpass their \$2,250 limit.

Dr. Joyce and colleagues looked at two employer health plans with drug benefits that had a cap on coverage of \$2,500, in order to get an idea of what is likely to happen with the Medicare plan.

In the years considered (2003 and 2004), 7% of beneficiaries in one plan and 11% in the other plan hit the cap.

The median time of year when patients hit the cap was September. However, one quarter of the patients who hit the cap did so in June, meaning they had no drug coverage for a full 6 months, Dr. Joyce said.

Patients did not appear to switch from brand-name drugs to generic drugs in any appreciable degree when they reached the cap. However, some patients did stop taking certain drugs. The most common medications the patients stopped taking were antidepressants and cholesterol-lowering drugs.

What was most concerning about those who stopped was that only about 40% of those who stopped then restarted those drugs at the beginning of the new year, Dr. Joyce said.

Previous studies of drug benefit caps have shown that they do reduce plan costs significantly. In one study of a Kaiser Permanente plan, a cap resulted in 31% lower drug costs. Overall, the Kaiser study found that the capped plan did not result in higher medical care costs. But there were more hospitalizations and more emergency department visits in the capped plan, compared to a noncapped plan. There was also a 22% higher mortality among patients in the capped plan. ■

With the Pap alone,
you don't see the
complete picture.

FIND DISEASE **THE DIGENE® HPV TEST** PREDICT RISK

DNAwithPAP

Even newer liquid-based cytology techniques can miss as much as 35% of CIN 3 or cancer.¹ But a Pap combined with The Digene® HPV Test* detects the cause of high-grade cervical disease and cancer with sensitivity as high as 100%.² It can also identify women at risk of developing disease in the future.³ So if you're not supplementing the Pap with The Digene® HPV Test in women age 30 and older, imagine what you might be missing.

1. ACOG Practice Bulletin, Clinical management guidelines for obstetrician-gynecologists, Number 61, April 2005. Human Papillomavirus. *Obstet Gynecol.* 2005;105:905-918. 2. Loricz AT, Richart RM. Human papillomavirus DNA testing as an adjunct to cervical screening programs. *Arch Pathol Lab Med.* 2003;127:959-966. 3. Wright TC, et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. *Obstet Gynecol.* 2004;103:304-309.

The Digene® HPV Test was approved by the US FDA and is also known to laboratories and physicians as the “Hybrid Capture 2 High-Risk HPV DNA Test” and the “DNAwithPAP test.” This does not refer to the Digene® product that tests for several types of the virus commonly referred to as “low-risk HPV,” which is not associated with cervical cancer.

DIGENE 800-DIGENE1 • www.digene.com

Digene and The Digene HPV Test are registered trademarks of Digene Corporation. DNAwithPAP and hc2 High-Risk HPV DNA Test are trademarks of Digene Corporation. © March 2006. Digene Corporation.

INDEX OF ADVERTISERS

3M Pharmaceuticals	
Aldara	26-27
Berlex, Inc.	
YAZ	3-4
Cytoc Corporation	
ThinPrep	9
Digene Corporation	
Digene HPV Test	38
Discovery Health Channel	
Corporate	7
Duramed Pharmaceuticals, Inc. (a subsidiary of Barr Pharmaceuticals)	
ParaGard	19-22
Enjuvia	24a-24d
Cenestin	31-32
Endo Pharmaceuticals Inc.	
Opana	13-15
ETHICON, Inc.	
TVT	48
LaserScope	
Corporate	16
LifeBank	
Placenta Cord	30
Martek Biosciences Corporation	
Corporate	5
McNeil-PPC, Inc.	
Monistat	29
Merck & Co., Inc.	
Gardasil	32a-32d
Corporate	36-37
Novo Nordisk Inc.	
Vagifem	23-24
OraSure Technologies, Inc.	
Histofreezer	35
Wyeth Consumer Healthcare	
Caltrate	16a-16b
Wyeth Pharmaceuticals Inc.	
PREMARIN	11-12